Prognostic and therapeutic implications of the MIB-1 labeling index in breast cancer

Breast Cancer

Volumn 5, Issue 3, 1998, Pages 255-259

  Nakagomi, Hiroshi ^a   Miyake, Tomoo ^a   Hada, Masao ^a   Hagiwara, Jun ^a   Furuya, Kazushige ^a   Muto, Shunji ^a   Koshizuka, Kohzo ^a   Takano, Kunio ^a   Kato, Ryohei ^b   Imamura, Koichi ^c   Oyama, Toshio ^d   Tada, Yusuke ^a  

^a Second Department of Surgery   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c Department of Surgery ^*  (Japan)

^d Yamanashi Prefectural Central Hospital   (Japan)

Author keywords

Breast cancer; MIB 1 labeling index

Indexed keywords

EID: 0004011054     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966705     Document Type: Article

References (20)

1. Clayton F: Pathologic correlates of survival in 378 lymph node negative infiltlating ductal carcinomas; Mitotic count is the best single indicator. Cancer 68:1309-1316, 1991.
2. Hery M, Giann J, Lalanne CM, et al: The DNA labeling index; A prognostic factor in node-negative breast cancer. Breast Cancer Res Treat 9:207-212, 1987.
3. Cooke TG, Stanton PD, Winstanley J, et al: Long-term prognostic significance of thymidine labelling index in primary breast cancer. Eur J Cancer 28:424-426, 1992.
4. Charpin C, Andrac L, Vacheret H, et al: Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast cancer. Cancer Res 48:4368-4374, 1988.
5. Brown RW, Allred DC, Clark GM, et al: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585-592, 1996. (Pubitemid 26099178)
6. Walker RA, Camplejohn RS: Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer 57:281-283, 1988. (Pubitemid 18096335)
7. Sahin AA, Ro J, Ro JY, et al: Ki-67 Immunostaining in node-negative stage I/II breast carcinoma. Cancer 68:549-557, 1991.
8. Key G, Becker MH, Baron B, et al: New Ki-67 equivalent murine monoclonal antibodies (MIB-1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 68:629-636, 1993. (Pubitemid 23202791)
9. Dupont W, Page LD: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146-151, 1985. (Pubitemid 15192861)
10. Katoh R, Bray CE, Suzuki K, et al: Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 26:139-146, 1995.
11. Abe O, Fukami A, Hirota T, et al: General Rules for Clinical and Pathological Recording of Breast Cancer, 12th ed, Kanehara, Tokyo, 1996.
12. Silverstein MJ, Lagios MD, Craig PH, et al: A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267-2274, 1996. (Pubitemid 26162419)
13. Clark MG: Prognostic and predictive factors. In: Harris JR, Hellman S, Henderson IC, Kinne DW eds, Breast Disease, LB Lippincott Co, Philadelphia, pp461-480, 1996.
14. Fisher B, Bauer M, Wickerham DL, et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer; An NSABP update. Cancer 52:1551-1556, 1983.
15. Gee J M W, Douglas-Jones A, Hepburn P, et al: A cautionary note regarding the application of Ki67 antibodies to paraffin-embedded breast cancers. J Pathol 177:285-293, 1995.
16. Veronese S, Maisano C, Scibilia J: Comparative prognostic value of Ki67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 16:2717-2722, 1996.
17. Remmele W, Muhlfait V, Keul HG: Estimation of the proliferative activity of human breast cancer tissue by means of the Ki67 and MIB-1 antibodies; Comparative studies on frozen and paraffin secions. Virchow Arch 426:435-439, 1995.
18. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal staging and of limited axillary dissection as a determination of histological nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765-772, 1981. (Pubitemid 11072899)
19. Bloom H J G, Richardson WI: Histological grading and prognosis in breast cancer; A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-375, 1957.
20. Le Doussal V, Redmond C, Fisher S, et al: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR); An improved sore modification based on a multivariate analysis of 1262 invasive ductal carcinoma. Cancer 64:1914-1921, 1987. (Pubitemid 19267813)